Filing summary
Entity and period: The supplied filing is AntriaBio, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2014 (its fiscal first quarter of 2015), filed November 12, 2014. It does not identify Rezolute, Inc.; investors should confirm that this is the intended filing. AntriaBio describes itself as a preclinical-stage company developing sustained-release therapeutics, including AB101, a once-weekly basal insulin candidate.
Financial results and liquidity
| Metric | Three months ended Sep. 30, 2014 | Comparable 2013 period |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $2.235 million | $0.701 million |
| Operating loss | $2.235 million | $0.701 million |
| Net loss | $2.215 million | $0.820 million |
| Net loss per share, basic and diluted | $0.12 | $0.12 |
| Net cash used in operating activities | $1.469 million | Cash provided: $3,671 |
The company reported no revenue and no meaningful operating margin; gross margin is not applicable. Cash was $4.298 million at September 30, down $1.637 million from June 30. Total assets were $6.267 million, total liabilities $1.248 million, and stockholders’ equity $5.019 million. Current assets were $4.696 million and current liabilities $0.893 million. The filing states working capital of $3.819 million, although those balance-sheet totals imply approximately $3.803 million.
Accounts payable and accrued expenses included $381,806 owed to related parties. Convertible notes payable were $60,000; the remaining notes had matured and were due on demand while continuing to accrue interest at 8%. Capital-lease obligations totaled $184,877, and the company disclosed $2.102 million of minimum future rent commitments. Cash paid for interest and taxes was zero.
Changes versus the prior period
Net loss increased about 170% year over year, while operating expenses more than tripled. Compensation and benefits rose to $1.013 million from $358,453, reflecting higher stock-based compensation and more full-time employees. Consulting expense increased to $283,633 from $81,274, principally for laboratory setup; investor-relations expense rose to $315,685 from $14,119; and general and administrative expense increased to $164,641 from $17,391. The company recorded $589,007 of stock-based compensation and $238,001 of stock issued for services in the quarter.
Operating cash use was $1.469 million, compared with near break-even operating cash flow in the prior-year quarter. The company acquired $168,037 of fixed assets for cash and also recorded $184,877 of equipment acquired through a capital lease and $148,730 of tenant improvements as noncash transactions.
Outlook, risks, and notable items
- Management estimated ordinary operating expenses at $350,000–$500,000 per month and said current cash could fund operations into the second half of calendar 2015. It also said the cash was insufficient for planned clinical development and estimated a need for at least $10 million in additional funding.
- Planned spending included approximately $2.5 million for a manufacturing-suite buildout, about $1 million for additional or replacement equipment, and approximately $4 million for a clinical study planned for the second half of 2015. Management planned additional IND-enabling studies, an FDA IND filing in 2015, and a Phase 1/2a program, subject to funding and development progress.
- The filing states that cash resources and expected operating cash flows would not sustain operations for more than one year and that substantial doubt existed about the company’s ability to continue as a going concern. Continued operations depended on raising capital; additional equity could materially dilute shareholders, and financing availability and terms were uncertain.
- In 2014, the company raised more than $11 million, including approximately $7.6 million net proceeds from an equity placement. At September 30, it had 18,217,793 common shares outstanding; the placement and outstanding warrants represent potential dilution.
- The company’s asset purchase agreement for PR Pharmaceuticals assets originally allowed up to $44 million of contingent payments. On November 6, 2014, after quarter-end, it paid $55,000 to acquire those payment obligations and was no longer liable for them. No contingent milestones had occurred through the filing’s report date.
- Management reported ineffective disclosure controls due to a material weakness involving insufficient segregation of duties and the need for a stronger internal-control environment, attributed to the small staff. It reported no material change in internal control over financial reporting during the quarter.
- No material litigation was reported. The filing stated there were no material changes to the risk factors in its latest Form 10-K.
Key facts for investors to verify
- Confirm that AntriaBio’s September 30, 2014 filing—not a Rezolute filing—is the intended document.
- Reconcile the reported $3.819 million working capital with the balance-sheet calculation of approximately $3.803 million.
- Check subsequent financing, cash runway, and whether the planned $10 million funding need and clinical/manufacturing costs were met.
- Verify the status and terms of the matured $60,000 notes payable and any continuing interest or demand for repayment.
- Assess AB101’s development milestones, regulatory progress, and the company’s ability to fund IND-enabling work and clinical trials.
- Review dilution exposure from stock options and warrants and monitor remediation of the disclosed material weakness in controls.